Key player · Company profile
Boehringer Ingelheim International GmbH
Named as a key player in 132 of our reports, across 33 regions and countries.
Named as a key player in 132 of our reports, across 33 regions and countries.
2023–2033 CAGR · estimates
Australia 4
Brazil 4
Canada 4
China 4
Ecuador 4
Egypt 4
France 4
Germany 4
Hong Kong 4
India 4
Italy 4
Japan 4
Kenya 4
Malaysia 4
Mexico 4
New Zealand 4
Philippines 4
Russia 4
Saudi Arabia 4
Singapore 4
South Africa 4
Spain 4
Thailand 4
UAE 4
UK 4
US 4| Market | Category | World 2023 | CAGR |
|---|---|---|---|
| Over The Counter (OTC) Drugs | OTC & Nutraceuticals | $178 Bn | 4.7% |
| Over The Counter (OTC) Analgesics | OTC & Nutraceuticals | $22 Bn | 3.4% |
| Anthelmintic Drug | OTC & Nutraceuticals | – | – |
| Anti-Venom | Pharmaceuticals | – | – |
Named as key players in the same markets as Boehringer Ingelheim International GmbH (number of shared markets).
Bayer AG3 shared markets
GSK PLC3 shared markets
Novartis AG3 shared markets
Johnson & Johnson2 shared markets
Merck & Co., Inc.2 shared markets
Reckitt Benckiser Group PLC2 shared markets
Sun Pharmaceutical Industries Ltd.2 shared markets
Amneal Pharmaceuticals, Inc1 shared market
Search all reports for Boehringer Ingelheim International GmbH All companies